New synthetic antibiotics could defeat MRSA and prevent relapsing infections

Antibiotic resistance continues to push modern medicine into dangerous territory. In hospitals around the world, infections ...
Healio

Evobrutinib nonsuperior to teriflunomide for relapsing forms of MS

Please provide your email address to receive an email when new articles are posted on . Permanent discontinuation due to treatment-emergent adverse events occurred in 12% and 10.6% of treatment groups ...
Monthly Prescribing Reference

High Dose Ocrelizumab Shows No Added Benefit for Relapsing MS Patients

Findings confirmed the approved 600mg IV dose was optimal for slowing disability progression in relapsing MS. A phase 3 study evaluating a higher dose of ocrelizumab in adults with relapsing multiple ...
Medical Xpress

Rituximab not noninferior to ocrelizumab for relapsing-remitting multiple sclerosis

For patients with relapsing-remitting multiple sclerosis (MS), rituximab is not noninferior to ocrelizumab, according to a study published online June 12 in JAMA Neurology. Izanne Roos, M.B.Ch.B., ...
Healio

FDA approves Tysabri biosimilar Tyruko for relapsing forms of multiple sclerosis

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Tyruko, the first biosimilar to Tysabri injection, for the treatment of adults with ...
Yahoo Finance

Sandoz receives FDA approval for Tyruko® (natalizumab-sztn), first and only FDA-approved biosimilar for relapsing forms of multiple sclerosis

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Monthly Prescribing Reference

Briumvi Approved for Relapsing Forms of Multiple Sclerosis

The approval was based on data from the phase 3 ULTIMATE 1 and ULTIMATE 2 trials that compared ublituximab-xiiy to teriflunomide in patients with relapsing multiple sclerosis. The Food and Drug ...
National Institute for Health and Care Excellence

Ofatumumab for treating relapsing multiple sclerosis

The appraisal committee considered evidence submitted by Novartis, and a review of this submission by the evidence review group (ERG). See the committee papers for full details of the evidence. The ...